



RNS REACH

4 August 2022

ImmuPharma PLC
("ImmuPharma" or the "Company")

INVESTOR PRESENTATION
Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin, COO, will provide a live investor presentation via the Investor Meet Company platform today, 4 August 2022 at 12:00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am today or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet **IMMUPHARMA PLC** via: <https://www.investormeetcompany.com/immupharma-plc/register-investor>

Investors who already follow **IMMUPHARMA PLC** on the Investor Meet Company platform will automatically be invited.

Ends

For further information please contact:

| | |
|--|----------------------|
| ImmuPharma PLC (www.immupharma.com) | +44 (0) 207 206 2650 |
| Tim McCarthy, Chairman and Chief Executive Officer | |
| Lisa Baderoon, Head of Investor Relations & Non-Executive Director | + 44 (0) 7721 413496 |
| SPARK Advisory Partners Limited (NOMAD) | +44 (0) 203 368 3550 |
| Neil Baldwin | |
| Stanford Capital Partners (Joint Broker) | +44 (0) 20 3650 3650 |
| Patrick Claridge, John Howes, Bob Pountney | |
| SI Capital (Joint Broker) | +44 (0) 1483 413500 |
| Nick Emerson | |

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

The new international Phase 3 trial for Lupuzor™ is being funded by Avion, who have the exclusive rights to commercialise Lupuzor™ in the US. The rest of the world rights remain with ImmuPharma and partnering discussions will be an integral part of creating further opportunities for Lupuzor™ in Lupus and the P140 platform across several additional indication targets going forward. The next indication being Chronic inflammatory demyelinating polyneuropathy (CIDP)

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Lupus (Systemic Lupus Erythematosus / SLE)

Lupus is a chronic inflammatory disease which is thought to affect some 5 million individuals worldwide. The current standard of care still consists of drugs which have many side-effects and limited efficacy. Despite the need for an effective treatment, only two therapies, namely GlaxoSmithKline's Benlysta and more recently, Astra Zeneca's Saphnelo, have been approved to treat the condition over the past 50 years. As such, there clearly exists an unmet medical need for a drug that has a strong efficacy and safety profile.